BridgeBio Pharma Inc.

11/16/2026 | Press release | Distributed by Public on 11/16/2026 13:04

Long-Term Effects of Acoramidis on Mortality in Variant Transthyretin Amyloid Cardiomyopathy, Including p.Val142Ile: Findings From the Open-Label Extension of ATTRibute-CM

BridgeBio Pharma Inc. published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 16, 2026 at 19:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]